drugset / Trial / NCT02641730

An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

NCT02641730

Phase 3 Completed 159 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab for the treatment of participants with palmoplantar pustulosis.

Timeline

Start
2015-12-15
Primary completion
2017-03-28
Completion
2018-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody 100 mg Subcutaneous
Subject Guselkumab Monoclonal antibody 200 mg Subcutaneous